ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-2.69%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$195M
AUM Growth
+$195M
(-21%)
Cap. Flow
-$49.9M
Cap. Flow
% of AUM
-25.63%
Top 10 Holdings %
Top 10 Hldgs %
61.32%
Holding
71
New
16
Increased
14
Reduced
19
Closed
22
Top Buys
| 1 |
Becton Dickinson
BDX
|
$17.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$16.7M |
| 3 |
Sabra Healthcare REIT
SBRA
|
$8.39M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$6.75M |
| 5 |
Qiagen
QGEN
|
$6.35M |
Top Sells
| 1 |
Labcorp
LH
|
$10.5M |
| 2 |
Centene
CNC
|
$8.77M |
| 3 |
Merck
MRK
|
$8.13M |
| 4 |
Icon
ICLR
|
$6.85M |
| 5 |
Viking Therapeutics
VKTX
|
$6.26M |
Sector Composition
| 1 | Healthcare | 91.98% |
| 2 | Real Estate | 8.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Thermo Fisher Scientific
TMO
$186B
| $2.16M | 1.11% | 3,744 +2,155 | +136% | +$1.24M |
|
|
27
Centene
CNC
$14.3B
| $1.87M | 0.96% | 29,586 -138,777 | -82% | -$8.77M |
|
|
ADAP
28
Adaptimmune Therapeutics
ADAP
$15.6M
| $1.81M | 0.93% | 1,660,835 -72,401 | -4% | -$78.9K |
|
|
BLUE
29
DELISTED
bluebird bio
BLUE
| $1.67M | 0.86% | +525,059 | New | +$1.67M |
|
|
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.57M | 0.81% | +64,704 | New | +$1.57M |
|
|
GRTS
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.5M | 0.77% | 540,657 +257,722 | +91% | +$716K |
|
32
Cencora
COR
$56.5B
| $1.47M | 0.75% | 9,153 -11,881 | -56% | -$1.9M |
|
33
Encompass Health
EHC
$12.3B
| $1.43M | 0.74% | 26,471 -51,673 | -66% | -$2.8M |
|
34
uniQure
QURE
$896M
| $1.43M | 0.73% | +71,040 | New | +$1.43M |
|
35
Zoetis
ZTS
$69.3B
| $1.4M | 0.72% | 8,414 -8,314 | -50% | -$1.38M |
|
36
Baxter International
BAX
$12.7B
| $1.4M | 0.72% | 34,508 +23,500 | +213% | +$953K |
|
37
ResMed
RMD
$40.2B
| $1.39M | 0.71% | +6,345 | New | +$1.39M |
|
38
Zimmer Biomet
ZBH
$21B
| $1.2M | 0.62% | +9,283 | New | +$1.2M |
|
|
39
Viking Therapeutics
VKTX
$3.04B
| $950K | 0.49% | 57,043 -375,992 | -87% | -$6.26M |
|
40
Aclaris Therapeutics
ACRS
$209M
| $679K | 0.35% | +83,891 | New | +$679K |
|
|
CTLT
41
DELISTED
CATALENT, INC.
CTLT
| $601K | 0.31% | 9,144 -26,121 | -74% | -$1.72M |
|
42
Iovance Biotherapeutics
IOVA
$807M
| $492K | 0.25% | 80,455 +9,800 | +14% | +$59.9K |
|
43
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $444K | 0.23% | +64,956 | New | +$444K |
|
44
89bio
ETNB
$1.34B
| $298K | 0.15% | 19,585 -17,199 | -47% | -$262K |
|
45
Maravai LifeSciences
MRVI
$350M
| $291K | 0.15% | 20,753 -705 | -3% | -$9.88K |
|
46
BioXcel Therapeutics
BTAI
$59M
| $217K | 0.11% | +11,640 | New | +$217K |
|
47
Biodesix
BDSX
$62.6M
| $211K | 0.11% | 113,267 -11,163 | -9% | -$20.8K |
|
|
ADXN
48
Addex Therapeutics
ADXN
| $114K | 0.06% | +120,748 | New | +$114K |
|
|
ATNX
49
DELISTED
Athenex, Inc. Common Stock
ATNX
| $56.7K | 0.03% | 42,651 -859,585 | -95% | -$1.14M |
|
50
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – | -4,596 | Closed | -$1.09M |
|